ESTRO 2024 - Abstract Book

S1102

Clinical - Gynaecology

ESTRO 2024

Conclusion:

While for prostate cancer ENRT apparently provides superior disease-free survival vs SBRT[6,7,8], the two therapeutic options obtain similarly good results in terms of disease-free survival, with acceptable toxicity, for gynecological tumors. OS remains low for both modalities, as already observed [1-5]. SBRT could be preferred for small treatment volumes. Prospective studies with adequate samples are needed to provide more complete information concerning the treatment of gynecological cancers.

Keywords: Gynaecological, SBRT, Lymph node

References:

1. Grigsby PW, et al. Recurrent carcinoma of the cervix exclusively in the paraaortic nodes following radiation therapy. Int J Radiat Oncol Biol Phys 1993; 28 : 451-455.

2. Vargo JA, et al. Extended field intensity modulated radiation therapy with concomitant boost for lymph node positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int J Radiat Oncol Biol Phys 2014; 90 (5): 1091-1098 3. Macchia G, et al. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist. 2020 Feb;25(2):e311-e320.

4. Macchia G, et al. Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study): a collaboration of MITO, AIRO GYN, and MaNGO groups. Int J Gynecol Cancer. 2022 Jun 6;32(6):732-739.

5. Macchia G, et al. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2/RAD): A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):321-332.